Navigation Links
MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
Date:7/24/2008

NEW YORK, July 24 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced results of a Phase 2 clinical trial involving 37 patients who completed a 48-week, U.S. multi-center, open-label efficacy and safety study of EcoNail, a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). The composite primary efficacy endpoint of the trial was "complete cure" defined as negative mycology (negative fungal culture and negative KOH) and clear nail (as determined by expert panel review of clinical photographs). EcoNail is the company's patented, topically-applied lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA(R).

A protocol-mandated, external expert panel assessed clinical photographs of 37 onychomycosis patients who completed 48 weeks of EcoNail treatment. The panel observed that 24 patients (65%) showed evidence of clinical improvement, defined in the protocol as an increase in uninvolved (clear) nail area. While none of the 37 patients reached all criteria of the composite primary endpoint, the consensus judgment of the panel was that 15 of 37 patients (41%) demonstrated significant (greater than or equal to 25%) clinical improvement. All patients had fungal culture-proven nail infections at entry, but after 48 weeks of once-daily treatment with EcoNail, 100% of patients had cultures that were negative for dermatophyte growth. Eight of the 37 patients (22%) achieved the secondary endpoint of negative mycology (negative fugal culture plus negative KOH evaluation) at 48 weeks. The panel observed no signs of local irritation related to the once-daily EcoNail treatment. During the trial, no patient required interruption of dosing due to local intolerability. Through 56 weeks of observation, no cutaneous adverse events were attributed by the investigators to EcoNail.

The laboratory of Boni Elewski, MD, Professor of Dermatology at the University of Alabama-Birmingham, perf
'/>"/>

SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
4. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
5. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
6. Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... be Presented, PRINCETON, N.J., Sept. 4 ... nine clinical abstracts for ipilimumab,an investigational anti-CTLA-4 antibody, ... presentations at the 33rd Congress of the European ... 2008 in Stockholm.,Many of the following abstracts will ...
... for Targeted Therapies ... Benefits of Personalized Treatment HUNTINGTON BEACH, ... leader in molecular cancer diagnostics,today announced the launch of ... determine the gene expression levels of,the estrogen receptor (ER), ...
Cached Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding dresses, ... business offers a wide range of special occasion dresses, ... them to create multiple looks easily. , According to ... of chic wedding dresses has been prepared for many ... rates now. Dylan Queen can always create what ladies ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication is ... states that, “While they give off the appearance of simplicity ... creating this powerful look.” , One of the first and ... kind of block matches your home environment and best fulfills ... main options are concrete and stone blocks. But do not ...
(Date:11/22/2014)... St. Petersburg, FL (PRWEB) November 22, 2014 ... Kitchen Innovations are pleased to announce that ... of the Thanksgiving #PayItForward contest. , Ms. Lombardo ... package from Kitchen Innovations. She wrote of how her ... beautiful, young daughters as a single mom. Despite medical ...
(Date:11/22/2014)... November 22, 2014 “Greenfield Naturals” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... the flavor of your water. , From pollution to ... important that everything is done to remove these chemicals, ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... Jerrold ... Connolly Medical Ltd. , ... (Vocus) January 29, 2010 -- Berkeley Heights – Jerrold S. Lozner, M.D., M.H.A., ... named as a “Top Doctor for Women’s Health” by Castle Connolly Medical, Ltd, in ...
... Pa. , Jan. 29 The Susan P. ... educate and inspire people of all ages to make healthy ... as President and CEO.  A talented non-profit leader, his goal ... expanding the delivery and distribution of health education services by ...
... , , Provides oral regime for hormone ... SPRING, Md. , Jan. 29 The U.S. ... with Femara (letrozole) to treat hormone positive and HER2-positive advanced ... indicated. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , HER2 ...
... respiratory weakness as a factor in the morbidity of ... that could improve long-term patient outcomes while reducing costs ... chair of research for the Department of Internal Medicine ... awarded a highly competitive, two-year, $480,000/year NIH Challenge Grant ...
... ... Following is the National Council on Disability,s monthly bulletin for December ... NCD,s award-winning Web site ( http://www.ncd.gov ), brings you the latest issues ... go to http://listserv.access.gpo.gov , click on "Online mailing list archives," select ...
... HANOVER TOWNSHIP, Pa. , Jan. 29 During a ... Secretary Everette James and Secretary of Education Gerald ... activity among middle school students. , "One-third of all Pennsylvania ... a lifetime of health problems," said James. "Schools like Hanover ...
Cached Medicine News:Health News:Summit Medical Group Physician Named 'Top Doctor for Women's Health' 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 3Health News:FDA Expands Use of Approved Breast Cancer Drug 2Health News:FDA Expands Use of Approved Breast Cancer Drug 3Health News:Kentucky research looks at respiratory weakness in ICU morbidity 2Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:State Health, Education Leaders Applaud Luzerne County School for Boosting Physical Activity Among Students 2
... your camera upon arrival.,Our technician then makes note ... with a thorough customer quote. We respect that ... so well help you prioritize repairs. With customer ... , ISI uses only OEM or widely approved ...
... carefully inspects your equipment upon arrival. Our technician ... and provides you with a thorough customer quote. ... a tight budget so well help you prioritize ... repair begins., , ISI uses only OEM or ...
... Infinity™ AST single liquid stable reagent ... quantitative determination of AST in serum. ... only provides excellent stability and convenience ... against existing assays. The reagent is ...
... Konelab 30 is a fully automated, versatile ... analytical needs in mind. Konelab 30 is ... tests, specific proteins, therapeutic drugs, drugs of ... applications. Its flexibility also makes the analyzer ...
Medicine Products: